Scientist I, Analytical Chemistry Development

Biogen
0 reviews

Posted on: 18 Jan 2021

Research Triangle Park, NC

Apply on Company site Save this job

Job Description

Job Description

The Analytical Development Biochemistry and Chemistry Development group (AD BioCD) in RTP, NC is seeking a Scientist I, who will work within a cross-functional team to advance our portfolio in both protein and oligonucleotide (ASO) therapeutics. The candidate will provide expertise and knowledge in analytical method development, method troubleshooting, as well as implementation of new analytical technologies. The candidate should have extensive experience and knowledge in analytical techniques such as mass spectrometry and separation science.

Summary of Key Responsibilities:

* Develop, qualify and troubleshoot LC-MS based analytical methods for protein and antisense oligonucleotide (ASO) therapeutics.
* Author method development, qualification and characterization reports, technical memos, and SOPs
* Perform detailed protein and ASO characterization using advanced methodologies.
* Provide technical leadership such as critical review of data , troubleshooting assays, and training others on analytical methods. Share technical expertise with others and mentor junior scientists.
* Develop and implement new analytical technologies for protein and ASO characterization.
* Publish in scientific journals and/or present at internal or external scientific meetings.
* Represent and/or support AD in project teams.

Qualifications

* Strong background and technical expertise in analytical chemistry methodologies such as mass spectrometry, liquid chromatography and electrophoresis.
* Experience in protein and antisense oligonucleotide characterization using mass spectrometry
* Experience in analytical method development using liquid chromatographic and electrophoretic approaches, such as HILIC, SEC, RP, IEC, CE-SDS and icIEF is highly desirable
* Proficient in good documentation practices, data analysis, reporting and review.
* Ability to work independently in lab but with strong collaboration and communication skills.
* Excellent time management and organization skills.

Education:

PhD in Analytical Chemistry, Biochemistry, or related Biological Sciences + 0-2 years of relevant experience; MS degree in Analytical Chemistry, Biochemistry, or related Biological Sciences + 4-6 years of relevant experience;
BS degree in Analytical Chemistry, Biochemistry, or related Biological Sciences + 6-8 years of relevant experience.

Additional Information

The Analytical Development Biochemistry and Chemistry Development group (AD BioCD) in RTP, NC is seeking a Scientist I, who will work within a cross-functional team to advance our portfolio in both protein and oligonucleotide (ASO) therapeutics. The candidate will provide expertise and knowledge in analytical method development, method troubleshooting, as well as implementation of new analytical technologies.

Biogen

Cambridge, MA

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.

Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.

The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.